NCT06348407View on ClinicalTrials.gov

A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)

RecruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Moderate to Severe Allergic Asthma

Interventions

DRUG

IgE monoclonal antibody

omalizumab

Trial Locations (1)

210000

RECRUITING

Linfu zhou, Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER